AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer - European Medical Journal

AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer

Oncology
At the European Cancer Congress (ECC) 2015, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France, discusses AURELIA, an open-label, randomised, phase 3 clinical trial that was designed to evaluate bevacizumab combined with chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel or topotecan) for patients with platinum-resistant recurrent ovarian cancer.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>